Print Print
Presentation
Tuesday 2 September
3 September
DAY 1Charter 1Charter 2Charter 3Charter 4Exhibition - Central Hall 1
DAY 2
All times shown are GMT
DAY 1Charter 1Charter 2Charter 3Charter 4Exhibition - Central Hall 1
DAY 2
08:00 08:00
08:05 08:05
08:10 08:10
08:15 08:15
08:20 08:20
08:25 08:25
08:30 08:30
08:35 08:35
08:40 08:40
08:45 08:45
08:50 08:50
08:55 08:55
09:00 09:00
09:05 09:05
09:10 Innovations in Screening & Assay Development
Chairs: Alan Wise, TPP   Ryan Bingham, GSK  
Phenotypic Discovery & Cellular Imaging
Chairs: Marc Bickle, MaxPlanck   Christian Parker, Novartis  
Oncology Drug Discovery
Chairs: Prof John Hickman, AGON Consulting   Namir Hassan, Immunocore  
Core Technologies Forum
09:10 (5 mins)
Core Technologies, Forum  
09:10
09:15 High-Throughput Screening - Challenges & Opportunities
09:15 (45 mins)
Keynote Speaker: Lorenz Mayr, AstraZeneca  
Phenotypic assays in drug discovery
09:15 (45 mins)
Keynote Speaker: Daniela Gabriel, Novartis Institutes for BioMedical Research  
Systems medicine in acute myeloid leukemia (AML) and beyond
09:15 (45 mins)
Keynote Speaker: Olli Kallioniemi, Institute for Molecular Medicine Finland (FIMM)  
Sample Management - Is a fully integrated sample management capability the future?
Chairs: Clive Green, Astra Zeneca  
09:15
09:20 09:20
09:25 09:25
09:30 Process software applications at Titian
09:30 (15 mins)
Toby Winchester, Titian Software  
09:30
09:35 09:35
09:40 09:40
09:45 Research and biobanking at the Nottingham Health Science Biobank
09:45 (15 mins)
Balwir Matharoo-Ball, Nottingham University Hospital  
09:45
09:50 09:50
09:55 09:55
10:00 Flow cytometry as a drug screening platform
10:00 (30 mins)
Rob Jepras, GSK  
Three-dimensional imaging of spheroids and tissues with light sheet-based fluorescence microscopy (LSFM, DSLM, SPIM)
10:00 (30 mins)
Prof Ernst Stelzer, Goethe Universitat Frankfurt am Main  
Circulating Tumour Cells (CTCs) in Lung Cancer - biology, biomarkers and mouse models
10:00 (30 mins)
Caroline Dive, CRUK Manchester Institute  
Healthcare, pharmaceutical and biotechnology sectors
10:00 (15 mins)
James Craven, TTP Labtech  
10:00
10:05 10:05
10:10 10:10
10:15 Specialized biological sample and material management
10:15 (15 mins)
David Wilson, Fisher Bioservices  
10:15
10:20 10:20
10:25 10:25
10:30 Coffee Break 10:30
10:35 10:35
10:40 10:40
10:45 10:45
10:50 10:50
10:55 10:55
11:00 Structure based GPCR drug discovery
11:00 (30 mins)
Dr Alastair Brown, Heptares Therapeutics Ltd  
High Throughput/High Content Screen to Identify Modulators of Neutrophil Extracellular Trap (NET) Formation
11:00 (30 mins)
Axel Choidas, Lead Discovery Center GmbH  
PREDECT - A European PPP to improve predictability of pre-clinical models
11:00 (30 mins)
Ralph Graeser, Janssen  
Innovative Automation - What can we automate next ?
Chairs: Malcolm Crook
11:00
11:05 11:05
11:10 11:10
11:15 Management of system & IT requirements for new automation projects
11:15 (25 mins)
Jonathan Wingfield, AstraZeneca  
11:15
11:20 11:20
11:25 11:25
11:30 Poster Taster Talks Poster Taster Talks Poster Taster Talks 11:30
11:35 Flow Cytometry FRET for the autmatic & fast detection of protein interatctions
11:35 (10 mins)
Kerstin von Kolontaj, Miltenyi Biotec Gmbh  
Establishing a National Phenotypic Screening Centre in the UK
11:35 (10 mins)
Paul Andrews, Stem Cell Solutions   
Use of DNA repair Cell Based Assays to Determine Efficacy of ERCC1 Inhibitor Compounds
11:35 (10 mins)
Laura Stennett, MRCT  
11:35
11:40 Specifying new equipment and robots for automation systems
11:40 (25 mins)
Roger Northwood, Unilever  
11:40
11:45 Screening for novel inhibitors of thymidylate synthase (TS) using CETSA
11:45 (15 mins)
Helena Almqvist, Karolinska Institute   
Side by Side: an evaluation of 2D vs 3D Cell Culture plates
11:45 (15 mins)
Sophie Quick, AstraZeneca  
Glycolysis as a promising target for Breast & Ovarian cancer treatment
11:45 (15 mins)
Chrysi Xintaropoulou, University of Edinburgh  
11:45
11:50 11:50
11:55 11:55
12:00 Snapshot Presentations Snapshot Presentations Snapshot Presentations 12:00
12:05 Software requirements of new automation systems
12:05 (25 mins)
Rob Harkness, Labapps  
12:05
12:10 12:10
12:15 12:15
12:20 12:20
12:25 12:25
12:30 Safety DMPK Screening (Lunch Provided during session)
Chairs: Andrew Brown, GlaxoSmithKline  
Lunch, Exhibition, Poster viewing 12:30
12:35 12:35
12:40 Co-chair
12:40 (5 mins)
Joanne Bowes, AstraZeneca  
12:40
12:45 Discussion Leaders
12:45 (25 mins)
Mr Stephen Brough, GlaxoSmithKline  
12:45
12:50 12:50
12:55 12:55
13:00 PerkinElmer Workshop in Exchange 10 Tecan Workshop in Exchange 8 13:00
13:05 13:05
13:10 Discussion Leaders
13:10 (25 mins)
Helen Garside, AstraZeneca  
13:10
13:15 13:15
13:20 13:20
13:25 13:25
13:30 13:30
13:35 Discussion Leaders
13:35 (20 mins)
Tim Smith, Cyprotex  
13:35
13:40 13:40
13:45 13:45
13:50 13:50
13:55 Welcome from the ELRIG Chairman
13:55 (5 mins)
Sanj Kumar, ELRIG & DiscoverX  
13:55
14:00 Introduction to Plenary Keynote
14:00 (5 mins)
Peter Simpson, AstraZeneca  
Plenary Speaker Plenary Speaker Plenary Speaker 14:00
14:05 Genetic drivers of cancer growth and resistance mechanisms
14:05 (55 mins)
Keynote Speaker: Dr Susan Galbraith, AstraZeneca  
14:05
14:10 14:10
14:15 14:15
14:20 14:20
14:25 14:25
14:30 14:30
14:35 14:35
14:40 14:40
14:45 14:45
14:50 14:50
14:55 14:55
15:00 Primarily primary and then 3D: A full deck phenotypic HTS on primary calls and evaluation of 3D culture applications for secondary screening
15:00 (30 mins)
Ingo Kober, Merck Serono  
Drug Discovery for Human African Trypanosomiasis: Target-Based and Phenotypic Approaches
15:00 (30 mins)
Ian Gilbert, University of Dundee  
Shaping the immune contexture in human cancer
15:00 (30 mins)
Wolf H Fridman, University Paris-Descartes  
Complex, High Content and Biologics data
Chairs: Mr Joe Bradley, Scitegrity   David Lee, UCB   Mark Roberts, Tessella  
15:00
15:05 15:05
15:10 15:10
15:15 Complex Data
15:15 (15 mins)
Andy Vines, IDBS  
15:15
15:20 15:20
15:25 15:25
15:30 Adhirons - novel tools for drug discovery
15:30 (30 mins)
Darren Tomlinson, University of Leeds  
Utilisation of cell models from patient-derived iPSCs to further understand Parkinson's Disease
15:30 (30 mins)
Ann Macdonald, Thermo Fisher Scientific  
Immune Mediated Therapy for Cancer: Preclinical Assessment of Immunobiology and Combination Activity in vitro and in vivo
15:30 (30 mins)
Robert Wilkinson, MedImmune  
Complex Data
15:30 (15 mins)
Stephan Heyse, Genedata  
15:30
15:35 15:35
15:40 15:40
15:45 Complex Data
15:45 (15 mins)
Roland Knispel, ChemAxon - HELM Project  
15:45
15:50 15:50
15:55 15:55
16:00 Mass Spectrometry in the Hit to Lead phase of drug discovery: Applications today and options for tomorrow
16:00 (30 mins)
Jonathan Wingfield, AstraZeneca  
Phenotypic discovery in AstraZeneca
16:00 (30 mins)
Anna Collen, AstraZeneca  
ImmTACs: Bi-specific TCR-anti-CD3 fusions for potent redirected killing of cancer cells
16:00 (30 mins)
Joseph Dukes, Immunocore Ltd  
Complex Data
16:00 (15 mins)
Geoff Holdgate, AstraZeneca  
16:00
16:05 16:05
16:10 16:10
16:15 Complex Data
16:15 (15 mins)
Janette Phi, IntelliCyt  
16:15
16:20 16:20
16:25 16:25
16:30 Complex Data
16:30 (15 mins)
Dermott O'Callaghan, TRN  
Poster Viewing 16:30
16:35 16:35
16:40 16:40
16:45 16:45
16:50 16:50
16:55 16:55
17:00 17:00
17:05 17:05
17:10 17:10
17:15 17:15
17:20 17:20
17:25 17:25
17:30 Drinks Reception 17:30
17:35 17:35
17:40 17:40
17:45 17:45
17:50 17:50
17:55 17:55
18:00 18:00